Intrarenal Perfusion and Angiotensin II Levels Regulate In Vivo Angiotensin II Type 1 Receptor Imaging in the Kidney
To the Editor:
In the recent issue of Hypertension, Dr Szabo's group used novel positron-emission tomographic (PET) [ 11 C]KR31173 imaging to study the regulation of intrarenal angiotensin II type 1 (AT 1 ) receptor binding in a swine model of renal artery stenosis in vivo. 1 In this study, AT 1 11 C]KR31173 levels were clearly observed at 2 minutes, which were followed by marked increases in [ 11 C]KR31173 accumulation in the kidneys with stenosis at 30 minutes after injection of the radioligand. By contrast, most injected [
11 C]KR31173 already disappeared from normal kidneys and contralateral kidneys at 30 minutes. 1 These images were consistent with Ͼ70% reductions in intrarenal perfusion in the kidneys with renal artery stenosis compared with contralateral kidneys.
The finding that long-term lisinopril treatment did not alter intrarenal AT 1 receptor binding in pig kidneys with stenosis suggests that angiotensin I-converting enzyme (ACE) might not be adequately inhibited in this study. 1 It would be interesting to determine whether plasma renin activities (or concentrations) and circulating and intrarenal Ang II levels in these pigs were altered by long-term lisinopril treatment. These investigators have indeed nicely showed that intrarenal AT 1 receptor binding was inversely related to Ang II in dogs treated with high-or low-salt diet. 3 We also previously showed that increased renal perfusion by sodium nitroprusside decreased, whereas the ACE inhibitor perindopril increased, intrarenal AT 1 receptor binding in rats in vivo. 4 Long-term ACE inhibition with captopril also increased receptor-mediated intracellular uptake of [
125 I]-Val 5 -Ang II in mice in part because of the upregulation of intrarenal AT 1 receptors. 5 Thus, long-term lisinopril treatment should increase rather than abolish intrarenal AT 1 receptor binding in vivo, as suggested by this study. 1
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